알츠하이머병에서 임상약물시험의 최신 동향
= Recent Update of Clinical Drug Trials in Alzheimer’s Disease
저자[authors] 강희영,박경원
학술지명[periodical name] 대한신경과학회지
권호사항[Volume/Issue] Vol.33No.4[2015]
발행처[publisher] 대한신경과학회
자료유형[Document Type] 학술저널
수록면[Pagination] 252-258
언어[language] Korean
발행년[Publication Year] 2015
KDC[Korean Decimal Classification] 513
주제어[descriptor] Clinical trial,Disease-modifying treatment,Alzheimer’s disease
초록[abstracts]
[The prevalence of Alzheimer’s disease (AD) is increasing as the global population ages. Currently available treatments for AD target cholinergic and glutamatergic neurotransmission. There have been modest symptomatic effects, but disease modifying effects have not been accomplished. This is even true of clinical trials of bapineuzumab and solanezumab, two humanized monoclonal antibodies that bind amyloid. Therefore, innovations in clinical trial designs are necessary, including revised diagnostic criteria and treatment at the earliest stages of AD. Several prevention trials started in 2013, emphasizing these innovative principles of clinical trial design. In this review, we will discuss the paradigm shift for AD clinical treatment trials and ongoing preventative trials.]